NITYR

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Israel, Italy, Lithuania, New Zealand, Poland, United States

Active ingredients

The drug NITYR contains one active pharmaceutical ingredient (API):

1 Nitisinone UNII K5BN214699 - NITISINONE

Nitisinone is a competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase, an enzyme which precedes fumarylacetoacetate hydrolase in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with hereditary tyrosinemia type 1 (HT-1), nitisinone prevents the accumulation of the toxic intermediates maleylacetoacetate and fumarylacetoacetate. Read about Nitisinone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
NITYR Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A16AX04	Nitisinone	A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AX Various alimentary tract and metabolism products
Discover more medicines within A16AX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1777259
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8704, 8705, 8706
Country: IT	Agenzia del Farmaco	Identifier(s): 046919015
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1085966
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 20931, 20932, 20933
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100410083
Country: US	FDA, National Drug Code	Identifier(s): 70709-000, 70709-002, 70709-005